FDA Panel Votes on Pimavanserin for Alzheimer Disease Psychosis
Although not bound by the committee’s recommendations, the Agency does take them into consideration when making decisions on approval.
Although not bound by the committee’s recommendations, the Agency does take them into consideration when making decisions on approval.
Crenezumab is an investigational monoclonal antibody designed to neutralize neurotoxic oligomers, a form of beta-amyloid.
Researchers sought to assess the risk factors for dementia in older adults with atrial fibrillation.
In a large, prospective cohort study, researchers assessed the association between daily total physical activity and the risk of developing disabling dementia in the general Japanese population.
Researchers sought to determine whether concussions and a history of playing football influenced a possible association between ACEs and poor neuropsychiatric health.
UB-311 is an immunotherapeutic vaccine candidate that targets toxic forms of aggregated amyloid beta in the brain.
Researchers established the Florida Consortium for African American Alzheimer’s Disease Studies to identify genetic risk factors and novel plasma biomarkers for AD.
In preclinical studies, PRX012 has been shown to bind to beta amyloid plaques and oligomers with high affinity.
Researchers sought to investigate the associations between habitual caffeine intake, incident cognitive impairment, and neuropathology.
In a cross-sectional study, researchers compared COVID-19 infection and mortality rates from 2019 and 2020 among Medicare enrollees with Alzheimer disease and related dementias.